Latin America: How Regulatory Transparency Can Tackle Non-Comparable Biologics
Executive Summary
Non-comparable biologics are a common problem in Latin America as they could deter companies with true biosimilars from entering the market. Among the solutions are better regulatory transparency and action to deal with “non-comparables” already on the market, says FIFARMA, the Latin American Federation of Pharmaceutical Industry.
You may also be interested in...
Global Template for Sharing Biosimilar Assessment Data Suggested By Regulators Group
Proposal suggests condensing key data and findings into under 10 pages, published in English.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.